What cost components are relevant for economic evaluations of palliative care, and what approaches are used to measure these costs? A systematic review

Clare Gardiner¹, Christine Ingleton¹, Tony Ryan¹, Sue Ward² and Merryn Gott³

Abstract
Background: It is important to understand the costs of palliative and end-of-life care in order to inform decisions regarding cost allocation. However, economic research in palliative care is very limited and little is known about the range and extent of the costs that are involved in palliative care provision.

Aim: To undertake a systematic review of the health and social care literature to determine the range of financial costs related to a palliative care approach and explore approaches used to measure these costs.

Design: A systematic review of empirical literature with thematic synthesis. Study quality was evaluated using the Weight of Evidence Framework.

Data sources: The databases CINAHL, Cochrane, PsycINFO and Medline were searched from 1995 to November 2015 for empirical studies which presented data on the financial costs associated with palliative care.

Results: A total of 38 papers met our inclusion criteria. Components of palliative care costs were incurred within four broad domains: hospital care, community or home-based care, hospice care and informal care. These costs could be considered from the economic viewpoint of three providers: state or government, insurers/third-party/not-for-profit organisations and patient and family and/or society. A wide variety of costing approaches were used to derive costs.

Conclusion: The evidence base regarding the economics of palliative care is sparse, particularly relating to the full economic costs of palliative care. Our review provides a framework for considering these costs from a variety of economic viewpoints; however, further research is required to develop and refine methodologies.

Keywords
Palliative care, end-of-life care, health expenditure, economic evaluation, healthcare costs, costs and cost analysis, systematic review

What is already known about the topic?
• Economic evidence in palliative care is important for making decisions regarding allocation of resources.
• Economic research in palliative care is very limited.
• Little is known about the range and extent of costs that are involved in palliative care provision and approaches used to capture these costs.

What this paper adds?
• Components of palliative care costs are incurred within four broad domains: hospital care, community or home-based care, hospice care and informal care.

¹School of Nursing and Midwifery, The University of Sheffield, Sheffield, UK
²ScHARR, The University of Sheffield, Sheffield, UK
³The University of Auckland, Auckland, New Zealand

Corresponding author:
Clare Gardiner, School of Nursing and Midwifery, The University of Sheffield, Barber House Annexe, 3a Clarkehouse Road, Sheffield S10 2LA, UK.
Email: c.gardiner@sheffield.ac.uk
• Palliative care costs can be considered from the economic perspective of three providers: state or government, insurers/third-party/not-for-profit organisations and patient and family and/or society.
• A wide variety of costing approaches are used to derive costs; the majority are country specific.

**Implications for practice, theory or policy**
• Research should prioritise evaluations of the full economic costs of palliative care, rather than discrete elements of care.
• A framework for considering the components of costs to include in economic evaluations is presented and can be adapted for use in future research.
• Further research is required to develop and refine economic methodologies, particularly those which enable international comparisons to be made.

---

**Introduction**

Growing demands are being placed on palliative care services as a result of population ageing, extending palliative care to people with non-cancer diagnoses and increasing death rates. As a result, palliative care must compete with other areas of care for finite resources, within a highly competitive funding environment, so that resources can be allocated effectively. It is therefore important to understand the costs of palliative and end-of-life care in order to inform decisions regarding cost allocation. Health economic evaluations are widely used to aid decision-making with respect to healthcare services, including palliative care. The analysis of the comparative costs of alternative treatments or healthcare programmes is common to all forms of economic evaluation. Two of the most fundamental questions to be considered in such evaluations are as follows: (1) which costs should be considered and (2) what is the viewpoint for the analysis (i.e. from whose perspective are costs to be considered).³

Within the context of palliative care, the first of these questions is complicated by the nature of palliative care interventions which commonly include multiple interacting elements,⁴ meaning the type and extent of costs are often complex. The second question is complicated by the wide range of individuals and organisations who are involved in funding palliative care and the overlap between these different providers.⁵ Palliative care is currently provided across three settings: hospital, community or home-based and hospice. Where palliative care is provided in hospices and specialist inpatient units, these are often co-funded through public healthcare systems or insurers and third-party not-for-profit organisations. This means the adoption of a single ‘viewpoint’ for economic evaluation is often not appropriate. In addition, the financial costs to patients and family caregivers in palliative care are also significant, although this viewpoint has been particularly neglected and under-researched.⁶ Therefore, while well-evidenced and robust methods are available to guide economic evaluations in health care,⁷ the most appropriate methods to undertake such evaluations in the context of palliative care are unknown, due in large part to the complexity inherent within the discipline. Perhaps as a consequence of these methodological challenges, economic research in palliative care is very limited. Indeed, a 2011 report from the UK Department of Health identified a ‘stunning lack of good data surrounding the costs for palliative care in England’ (p. 9).⁸ The international evidence base regarding the economic dimensions of palliative and end-of-life care provision is similarly sparse.⁹ A recent study from Canada noted the narrow viewpoint that the majority of economic analyses have taken, highlighting that these have been limited to the measurement of publicly financed care without consideration of the considerable costs faced by other stakeholders, including patients and their families.¹⁰ These issues are further compounded by inconsistent definitions of palliative care internationally¹¹ which have hampered attempts to identify exactly what constitutes a palliative care cost.

It was within this context that we identified a need to synthesise the existing literature in order to inform much needed consideration of which costs are potentially relevant in economic evaluations of palliative care. Related to this, we also identified a need to consider the methods used to collect, and accurately cost, palliative care data with a view to providing methodological guidance for future economic evaluations in palliative care. The aim of this article is therefore to undertake a systematic review of the health and social care literature to determine the range of financial costs related to a palliative care approach and explore approaches used to measure these costs.

**Methods**

In order to increase methodological rigour and transparency, and provide clarity around the research aim, the following definitions have been applied to the key concepts of the review. A **palliative care approach** is defined as a comprehensive package of palliative care incorporating specialist and/or generalist elements. For the purposes of this review, specialist palliative care is defined as care provided by professionals who have undergone recognised specialist palliative care training and generalist palliative care is defined as palliative care provided as part of standard clinical practice by any healthcare professional who is
not part of a specialist palliative care team. The range of costs is defined as all elements or components of health and social care expenditure related to a palliative care approach, including costs to patients and/or family members and societal costs. Approaches to measuring costs are the methodological approaches used by researchers to capture and accurately cost economic data relating to a palliative care approach.

Four electronic databases (CINAHL, Cochrane, PsycINFO and Medline) were searched from 1995 to Nov 2015. A search strategy was devised by the authors in consultation with an information specialist (Table 1) and applied to title, keywords and abstracts. The search was limited to the last 20 years in recognition of the rapidly changing nature of funding and economic research and the limited relevance of research published pre-1995. The search comprised Medical Subject Headings (MeSH) and keywords related to the research question; an initial scoping search was undertaken in order to refine the search strategy. Appropriate wildcards were inserted to search for word ending truncations where necessary. Reference lists of included studies were hand-searched. We also undertook a comprehensive grey literature search of the following organisations: Marie Curie Cancer Care, Nuffield Trust, UK Department of Health, National Institute for Clinical Excellence (NICE), Kings Fund, World Health Organization (WHO), National Audit Office (NAO), Office for National Statistics, National Council for Palliative Care, National End of Life Care Intelligence Network, American Academy of Hospice and Palliative Medicine and US Department of Health and Human Services. All searches were undertaken in November 2015.

Title and abstracts of all articles were screened by C.G. to identify those which met the study inclusion criteria. Study inclusion criteria can be found in Table 2. The original intention had been to restrict inclusion to papers which reported the full economic cost of palliative care, that is, the costs incurred in all settings related to the receipt of a palliative care approach, from the viewpoint of all providers including state/government, third-party payer and society and patient/family. However, the scoping exercise identified very few papers that met this criterion so inclusion criteria were expanded to papers reporting costs in more than one setting or from the viewpoint of more than one provider.

Full texts of all included articles were independently screened by two of the four authors (C.G., M.G., C.I. and T.R.). Studies were again assessed to identify those which met the inclusion criteria. Where there was lack of consensus, a third person acted as arbitrator. Details of included studies were extracted onto pre-defined forms.

The scoping search indicated that studies included in the full review would be likely to have diverse methodologies and significant heterogeneity; therefore, a thematic synthesis method was chosen in order to achieve translation between the results of the diverse studies. The thematic approach guided data extraction and was based on pre-defined categories relating to the research aim. Data

### Table 1. Search terms.

| Palliative search terms               |
|--------------------------------------|
| MeSH                                 |
| terminal care*                       |
| terminally* ill                      |
| End of life care                     |
| Hospice                              |
| Additional keywords                  |
| Life-limiting                        |
| Cost search terms                    |
| MeSH                                 |
| Health expenditure                   |
| Health care costs                    |
| Costs and *cost analysis             |
| Additional keywords                  |
| Economic assessment                  |
| Economic evaluation                  |
| Economic implications                |
| Resource utilization                 |
| Resource consumption                 |
| Health care utilization              |
| Financial burden                     |
| Financial stress                     |
| Financial strain                     |

MeSH: Medical Subject Headings.

### Table 2. Inclusion and exclusion criteria.

| Inclusion criteria                                                                 | Exclusion criteria                                                                 |
|-----------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| • Papers must report costs of a palliative care approach                           | • Papers published before 1995 (i.e. older than 20 years) OR papers where all the  |
| (defined as a comprehensive package of care incorporating specialist and/or generalist elements). |  cost data were collected pre-1995.                                                |
| • Papers must report on full economic costs of palliative care, OR costs in more  | • Unpublished manuscripts, conference abstracts, posters and other empirical work not |
| than one setting or from the viewpoint of more than one provider.                  |  published in full.                                                                 |
| • No restrictions on country of publication.                                       | • Non-empirical articles, e.g., discussion papers, letters, editorials, commentaries.|
| • Original research (i.e. involving independent data collection) or literature     | • Foreign language papers with no translation.                                       |
| reviews published in full.                                                        | • Papers only reporting on costs which relate to specific element of care or specific  |
| • Papers relating to adults (>18 years).                                          |  interventions, e.g., costs of advanced care planning/hospice care/home care.      |
| • English language papers.                                                        |                                                                                     |
were extracted on the aim of the study, the design of the study, the components of costs, the data sources used and the methods used to collect cost data (Table 3).

Study quality was evaluated using the ‘Weight of Evidence Framework’, a method which structures quality and relevance appraisal in terms of three dimensions which involve both generic standards and review-specific assessments. This approach to quality appraisal is particularly recommended for reviews involving studies with diverse methodologies where traditional method–specific checklists are not appropriate. The first dimension is the quality of execution of the study according to generic and accepted standards associated with that type of study (methodological quality). The second dimension is the appropriateness of the study design for answering the review question (methodological relevance). The third dimension is how well matched the study is to the focus of the review (topic relevance). Studies were given a grading of 1–3 (low–high) for each dimension and scores totalled. Studies with a total score of <4 were excluded.

**Results**

Search results are summarised in the adapted Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flowchart in Figure 1. A total of 39 papers met our inclusion criteria; however, one scored poorly on study quality (<4) and was subsequently excluded resulting in a final total of 38 papers (Table 3).

All studies reported on a ‘palliative care approach’; however, the definition of palliative care differed across studies. The majority of studies were retrospective reviews of routine or claims’ data (n = 18) or prospective cohort studies (n = 10). Five studies were literature reviews, two were economic modelling studies, one a comparison group design, one a pilot study and one a methods development study. The majority of studies were from Canada (n = 11), the United States (n = 7) and the United Kingdom (n = 7). Quality scores of the included studies varied markedly, and only four received the top score of 9. In general, low scores reflected the lack of high-quality data with which to estimate costs, rather than poor methodological choices or poor topic relevance.

**Components of palliative care costs**

Included studies reported a wide range of costs that were associated with providing a palliative care approach. However, only eight papers (based on data from five studies) collected data on the full economic cost of palliative care including costs incurred in all settings, from the viewpoint of all providers. While some studies may have been conducted for a specific purpose which did not require full costs to be collected, the lack of comprehensive data on economic costs is concerning. Analysis of data from all included studies indicated that components of palliative care costs were incurred within four broad domains or settings: acute hospital care, community or home-based care, hospice care and informal care. These costs could be considered from the viewpoint of three providers: state or government, insurers/third-party/not-for-profit organisations and patient and family and/or society. Viewpoint differed significantly depending on the healthcare funding system of the country in which the research took place. Table 4 provides a framework of the core cost components which are potentially relevant in economic evaluations of palliative care and the viewpoints from which these costs can be considered.

Hospital costs comprised all costs relating to inpatient, outpatient and ambulatory care in hospital. Hospital costs were the most commonly captured, reflecting the fact that hospital care tends to form the largest financial component of end-of-life care. Hospital costs included those relating to inpatient admissions, outpatient admissions, emergency room (ER) visits and ambulatory care. Some studies included country or culturally specific costs, for example, Chan et al. evaluated palliative care costs in hepatocellular carcinoma in Hong Kong and included costs of Chinese medicines and herbal remedies. Only one study explicitly identified hospital overheads (building costs and capital depreciation, etc.) as a component of care costs, despite overheads accounting for a substantial 20% of the cost per patient per day in this study. Community or home-based care costs comprised all costs generated through care based in the community or in the patients’ own home. These costs were numerous and there was significant heterogeneity across studies in the nature of these costs, most notably between different countries. These costs included visits and associated costs from general practitioners (GP’s)/family physicians and community nurses, and also a wide range of additional ancillary costs such as those incurred from social services, support from allied health professionals and care provided in a range of day care and residential settings. Only one study specifically included costs of mental health care. Hospice care costs comprised all costs relating to inpatient and outpatient hospice care. They were broadly similar to those related to hospital care, but were usually recorded less comprehensively, perhaps as a consequence of the range and complexity of providers involved in funding hospice care and the differential definitions of hospice across the world. Costs incurred by patients and their families were included in only a small number of studies. Some of these costs represented direct costs to patients and family (i.e. direct outlays of money or out-of-pocket costs); however, others were assumed or indirect costs (i.e. income lost through illness or caregiving, or caregiver time costs). None of the included studies attempted to capture costs relating to lost productivity from the perspective of employers.
Table 3. Details of included studies.

| Author, country of origin | Aims                                                                 | Design                        | Approaches used to collect cost data and approach(es) used to derive costs                                                                 | Components of care costs                                                                 | Quality appraisal score |
|---------------------------|---------------------------------------------------------------------|-------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|------------------------|
| Bardsley et al., UK       | To describe patterns in use of health and social care by individuals. | Retrospective cohort study of 16,479 patients | Information collected from PCT routinely collected data. Inpatient costs based on national average unit costs. Social care costs derived from national unit costs (Personal Social Services Research Unit). | Data collected on hospital admissions and social care costs including residential care, nursing home, home care, residential respite care, equipment and adaptations, direct payments made to users who can they ‘buy’ their own service, day care meals | 6                     |
| Bentur et al., Israel     | Examined the utilisation and cost of all health services consumed during the last 6 months of life by cancer patients. | Retrospective review of administrative data of 193 cancer patients | Costs calculated according to official price list of Ministry of Health.                                                                 | General hospitalisation admissions, ER visits, medication, enrolment in home care unit, enrolment in home hospice unit and oncology day care. | 5                     |
| Chai et al., Canada       | Assess the magnitude and share of unpaid care costs in total healthcare costs for home-based PC patients. | Prospective cohort study design with repeat measures, 137 terminally ill patients | Used AHCR to collect data from caregivers. Human capital approach used to assign monetary value to caregiver time. | Publicly financed costs (all healthcare costs incurred by the public sector). Privately financed costs (costs paid by family caregivers; private insurance plans). Unpaid caregiving costs. | 9                     |
| Chai et al., Canada       | To assess publicly financed costs within a home-based setting from a societal perspective. | Prospective cohort study design with repeat measures | As above | As above | 9                     |
| Chan et al., Hong Kong    | To determine the patient-specific costs of PC of hepatocellular carcinoma from a societal perspective. | Prospective design, repeat measures with 204 patients | Hospital costs calculated using standard methods of Hospital Authority of Hong Kong. Medication costs based on formulary costs. Laboratory costs based on workload units and WELCAN workload units’ system. | Measured resources included short-term inpatient hospital care, continuing inpatient care and hospice care, outpatient services, Chinese and herbal medicines, supplies privately obtained and income lost by caregivers/patients | 5                     |
| Chastek et al., USA       | To examine EOL healthcare resource costs among oncology patients in a US commercial insurance population. | Retrospective analysis of claims’ database for 28,530 cancer patients | Cost data collected directly from medical claims’ database and pharmacy claims. | Cancer-related services including; medical and surgical acute cancer-related inpatient stays, cancer-related hospice care, supportive care, ER visits, cancer-related hospital outpatient procedures and other cancer services. | 6                     |
| Coyle et al., UK          | Examine costs of PC in the community setting, hospital and hospice and identify patient characteristics associated with increased costs of care. | Prospective cohort including 202 patients with non-curative disease | Patients interviewed in a baseline interview and then at 7, 28 days, 3 months. Costs were calculated based on national averages from Unit Costs Working Group. | Number of hospital and hospice inpatient stays and day care visits, outpatient visits, GP consultations, home visits, surgery, chemotherapy, radiotherapy. | 7                     |
| Dumont et al., Canada     | Evaluate prospectively resource utilisation and related costs during the palliative phase of care in Canada. | Prospective design with repeat measures, 160 palliative patients | Data collected from patients and caregivers using survey, every 2 weeks until patients’ death or max. of 6 months. Costing of goods and services included (a) quantities used and (b) unit costs. Alberta unit costs were used as standard costs, except for personal expenses, where participants provided the actual costs. | Inpatient hospital stays, ambulatory care, home care, long-term care, transportation, prescription medication, medical aids, out-of-pocket costs, carer time costs. | 9                     |
| Author, country of origin | Aims | Design | Approaches used to collect cost data and approach(es) used to derive costs | Components of care costs | Quality appraisal score |
|--------------------------|------|--------|---------------------------------------------------------------------------|--------------------------|------------------------|
| Dumont et al., 19 Canada | Aimed to highlight the trajectory of PC costs over the last 5 months of life in five urban centres across Canada. | As above | As above | As above | 7 |
| Dumont et al., 20 Canada | To evaluate the costs related to all resources used by rural PC patients and to examine how these costs were shared between the public healthcare system, patients’ families and not-for-profit organisations. | Prospective study with repeat measures in four rural regions of Canada | 82 Palliative patients and 86 caregivers using costing questionnaire, every 2 weeks until patients’ death or max. of 6 months. Costing strategy as above. | As above | 6 |
| Enguidanos et al., 21 USA | To examine differences in site of death and costs of services by primary diagnosis for patients receiving home-based PC as compared to usual care at the EOL. | A non-equivalent comparison group study design with 298 terminal patients | Patients interviewed at baseline and every 30 days until death. Costs of care calculated by multiplying number of visits or service days by the 1999 cost of staff time. Facility and administrative costs were not included. | Number of emergency department, physician office, home health and palliative care visits and number of days spent in the hospital and skilled nursing facility. Also number of days on hospice prior to death. | 5 |
| Georghiou and Bardsley, 22 UK | To estimate hospital and non-hospital costs for people in the last 90 days of life. | Retrospective study utilising a number of different patient cohorts | Data collected from various sources. GP, community nursing and social care costs calculated from unit cost estimates from the Personal Social Services Research Unit. Hospice inpatient costs estimated by commissioner charge per bed day. Hospital costs calculated from the Payment by Results national tariff. | Primary care (limited to GP consultations), community care (limited to district nursing care), local authority–funded social care, inpatient hospice care, secondary (acute hospital) care. Each cost element was captured from a separate patient cohort. | 6 |
| Gomez-Batiste et al., 23 Spain | To describe the consumption of healthcare resources by patients with advanced cancer in their last months of life in Spain. | Descriptive-observational, prospective, longitudinal, multicentre study of 372 cancer patients | Interviews with patient or carer every week for 16 weeks or until death. Cost/day for an inpatient unit and hospital costs was based on data from the Spanish Ministry of Health. Cost for a specialist PC bed and other non-hospital costs estimated based on previous literature as there were no reliable data. | Costs of home visit, hospital admission, PC unit admission, onco-ward, other services, visit to GP clinic, phone calls, PC outpatient clinic, casualty. | 6 |
| Guerriere and Coyte, 24 Canada | Addresses the methods used to measure EOL care costs. | A systematic literature review | Systematic review of 18 articles followed by proposal of AHCR, a tool to measure EOL costs. | AHCR includes all costs to public (ambulatory, inpatient, home) and private (third-party insurance, out-of-pocket, caregiver time, employer time). Prescribed drugs, GP, outpatient and domiciliary visits by a PC physician and hospital admissions. | 6 |
| Guest et al., 25 UK | To identify treatment patterns and corresponding costs of healthcare resource use associated with PC for different types of advanced cancer patients. | Modelling study using data from 547 cancer patients | Resource utilisation data were extracted from the DIN-Link database which captures data on patients managed by GPs. Unit resource costs obtained from published sources. Medication costs from MIMS and the Drug Tariff. | Data collected on last year of life from two linked national population registers which provide County Council expenditure. | 7 |
| Hanretty et al., 25 Sweden | To investigate the association between public expenditure on health care in the last year of life and individual socioeconomic status in Sweden. | Population-based retrospective study of public expenditure using linked registers, 16,617 deaths in Sweden | | County Council expenditure on health care as a hospital inpatient or outpatient, primary care utilisation and private outpatient consultations (which are also funded by the Council in Stockholm). | (Continued) |
| Author, country of origin | Aims | Design | Approaches used to collect cost data and approach(es) used to derive costs | Components of care costs | Quality appraisal score |
|--------------------------|------|--------|-------------------------------------------------|--------------------------|------------------------|
| Hanratty et al., UK      | To investigate the use of health and social services, payments and benefit receipt by individuals in differing financial circumstances in the year before death. | Analysis of individual level panel data for 1652 community-dwelling decedents | Data collected once per year and data from previous year to death used for analysis. No actual cost data collected, just resource use and financial strain. | Number of GP consultations, days spent as a hospital inpatient, district nurse or health visitor, physiotherapy OT or speech therapy, psychiatric services, chiropody, home help, meals on wheels, social work, other social services. | 6 |
| Hogan et al., USA        | Profiles Medicare beneficiaries’ costs for care in the last year of life. | Retrospective analysis of patient-level data from three national databases for 8000 patients | Actual costings taken from Medicare claims’ data, Medicare current beneficiaries survey, National Mortality Followback Survey. | Does not specify which aspects of resource use are captured in the three databases. | 5 |
| Hollander, Canada        | Provides a summary of data on healthcare costs for persons who died in Saskatchewan in the 2003–2004 fiscal year. | Retrospective analysis of detailed patient-level utilisation data for 8703 patients | For hospital costs, the RIW cost factor was used. Hospital data contain the number of RIWs used for a hospital stay. This number was multiplied by funding per weighted case to obtain the estimated funded cost of the hospital stay. Costs for prescription drugs, and physician services, are reported directly. For long-term care facilities, average regional cost was used. Data collected from three databases. | States ‘detailed utilisation data’ collected but does not provide details. Indicates this included hospital stays, stays in long-term care facilities and prescription drugs and physician services. | 4 |
| Hoover et al., USA       | To compare medical expenditures for the elderly (65 years old) over the last year of life with those for non-terminal years. | Retrospective panel survey of MCBS data for 49,505 patients | Data collected from MCBS data (MCBS data were collected at 4-month intervals to collect all medical costs by payer and service.). Medicare costs are validated by claims’ records. | All medical expenses. Medicare included inpatient hospital, outpatient hospital, prescription drugs, home health care, medical provider, dental services, hospice and facility. Non-Medicare included out-of-pocket, Medicaid and insurance. | 8 |
| Johnston et al., UK, Italy, France | To describe patterns of healthcare resource utilisation and associated costs for patients with advanced melanoma in the UK, Italy, and France. | Cohort study involving review of medical records of 611 melanoma patients | Data were obtained from medical records. Included both patients receiving supportive care and systemic care. Costs were estimated by multiplying utilisation level by unit cost. | Number and duration of hospitalisations, duration of hospice care, number of outpatient visits and the number of ER visits (ER data not used as negligible impact on overall cost). | 4 |
| Johnson et al., Canada   | To provide a detailed description of healthcare resource utilisation and costs of a pilot interdisciplinary healthcare model of palliative home care. | Pilot study, evaluating costs prospectively of 434 cancer patients | Data collected from admission into the programme until death. Costs taken from Ministry of Health, Ontario Drug Benefit and Health Insurers billings. | Personal support, laboratory costs, nursing, nutritional counselling, OT, physician costs, PC, drug costs, medical supplies, equipment – hospital beds, IV poles, bed pans, diapers. | 6 |
| Kaul et al., Canada      | To examine trends in resource use and costs during the last 6 months of life among elderly patients with HF. | Cohort retrospective review of medical records of 33,144 HF patients | Data collected for 6 months before death using medical records. Costs calculated by assigning costs using a case-mix grouping for each patient. Claims’ data also used to calculate physician costs and some hospital costs. | Resource use related to acute care hospitalisations, outpatient clinic visits, ER visits, physician services, pharmaceutical costs, continuing care facility, home care or other facility (e.g. hospice, disability service). | 5 |
| Author, country of origin | Aims | Design | Approaches used to collect cost data and approach(es) used to derive costs | Components of care costs | Quality appraisal score |
|---------------------------|------|--------|--------------------------------------------------------------------------|--------------------------|-------------------------|
| Kim et al., South Korea   | To investigate healthcare spending and utilisation in the last 12 months of life among patients who died with lung cancer. | Retrospective cohort study using nationwide lung cancer health insurance claims' data for 155,273 patients | Data collected for 12 months before death. Costs derived from health insurance claims' data, using the fee for services catalogue which is negotiated by the government, providers and other stakeholders every year. | Health insurance claim details including total inpatient/outpatient costs, patients' copayments (out-of-pocket costs) and payer costs | 7 |
| Koroukian et al., USA     | Evaluate the extent to which the Ohio Medicaid Programme serves as a safety net to terminally ill cancer patients and the costs associated with providing care to this patient population. | Retrospective cohort study using Medicaid and death certificate files for 44,509 cancer patients | Expenditures in the last year of life were aggregated using the Medicaid summary expenditures file. | Costs including but not limited to inpatient, outpatient, nursing home, pharmacy, hospice and physician services. | 6 |
| Kovacic et al., Serbia    | To assess major cancer cost drivers in Serbia. | Retrospective database analysis of 114 cancer patients | Costs collected from the official price list of the national RF-HI. | Costs relating to cancer healthcare services: primary care (included home care), hospital outpatient and hospital inpatient care. | 6 |
| Langton et al., Australia | To synthesise retrospective observational studies on resource utilisation and/or costs at the EOL in cancer patients. | Systematic review | Review of 71 articles that included at least one resource utilisation or cost outcome in cancer patients at the EOL. | 71 Studies reported outcome measures relating to resource utilisation, 30 of which examined only one aspect of resource use. | 6 |
| Ljungman et al., Sweden   | To report cost utility estimates for patients with unresectable pancreatic tumours who experienced PC only. | Retrospective population-based cohort study of 444 cancer patients | Data collected from diagnosis to death. Cost registry provided hospital costs per patient using local and national tariff data. Home and hospice costs estimated using local registry data to estimate tariff. | Total direct healthcare costs at departments of surgery and oncology, for primary health care and at hospice. | 7 |
| Marie Curie Cancer Care, UK | Considers the economic impact of providing care to patients in the community, rather than in the acute setting. | Review of evidence from multiple sources | Collection of cost data from various sources. Hospital costs based on submissions from both NHS trusts and PCTs. Community costs derived from previous literature, Personal Social Services Research Unit and Marie Curie tariffs. | Collects data on pall care in the community (district nursing, community nursing, social care, community nurse specialist, outpatient attendance) and in hospital (hospital inpatient specialist PC). | 4 |
| McBride et al., UK        | To explore the financial consequences of reduced acute utilisation and expanded community utilisation in the last year of life. | Markov (decision analytic) modelling study based on 127,000 cancer patients and 30,000 organ failure patients | Models costs of cancer and organ failure in the last year of life. Cost data derived from previous literature, mostly from Coyle et al. and inflated using Consumer Price Index. | Model attempted to capture costs over 365 days, whereby each day is spent in a specific 'state' (hospital, community or hospice) and probability of moving between states is calculated by the model. | 5 |
| Mosoiu et al., Romania    | To develop a standardised method for measuring the cost of PC delivery that could potentially be replicated in multiple settings. | Methodological development study on development of costing framework | Specific staff salaries, direct costs and indirect costs are based on Romanian laws currently in use in the public health system. Unit costs per day of admission based on Romanian Houses of Health Insurance tariff. | Inpatient costs included direct patient costs (personnel, bed days, drugs, etc.). Also overhead costs, building and capital depreciation. Home-based care costs included personnel, transport, medication, communication, indirect and start-up costs. | 5 |

Table 3. (Continued)
| Author, country of origin | Aims | Design | Approaches used to collect cost data and approach(es) used to derive costs | Components of care costs | Quality appraisal score |
|--------------------------|------|--------|-------------------------------------------------|--------------------------|------------------------|
| Simoens et al., Belgium  | To review the international literature on the costs of treating terminal patients. | Literature review | Included 15 studies on the costs of treating terminal patients. | Papers included costs of treating terminal patients across healthcare settings; costs of various treatment approaches, in different types of hospitals and in different types of units; and costs of different models to treat terminal patients at home. | 7 |
| Smith et al., Ireland    | To review literature of available international evidence on the costs and cost-effectiveness of PC interventions in any setting over the period 2002–2011. | Systematic review | Includes 46 papers on the cost and/or utilisation implications of a PC. Variation in the cost data used with some studies relying on charges, others on observed expenditures and the remaining on detailed bottom-up estimates based on actual resource use. | The main focus of the studies is on direct costs, from the provider or third-party payer perspective, with little focus on informal care or out-of-pocket costs. | 6 |
| Tamir et al., Israel      | To evaluate health services utilisation during the last year of life and to compare terminally ill patients who have received HSPCs with patients who did not. | Retrospective cohort study of 120 HSPC patients and 515 controls | Data collected for last year of life. Data retrieved from databases of national insurance provider (who is both the buyer and provider of services). No further details on costing approach. | Costs: ambulatory procedures, imaging, laboratory, consultations, hospitalisation, day hospitalisation, ER, doctor visit, oncology treatment, other. All included costs covered by national insurance provider. | 4 |
| Tangka et al., USA       | To quantify EOL medical costs for adult Medicaid beneficiaries diagnosed with cancer. | Retrospective review of Medicare for 3512 beneficiaries with cancer | Data collected for last 4 months of life. Costs calculated using Medicare insurance claims. | Costs: hospital admissions, ambulatory care services, prescription drugs, long-term care and all palliative treatments. | 7 |
| Unroe et al., USA        | To examine healthcare resource use in the last 6 months of life among elderly Medicare beneficiaries with HF. | Retrospective cohort study using Medicare claims’ data for 229,543 patients with HF | Costs calculated using Medicare claims’ data. | Costs relating to hospitalisations, skilled nursing facilities, hospice care, home health care and durable medical equipment. | 7 |
| Walker et al., Canada    | To estimate costs of end-of-life care for cancer patients in the last 6 months of life. | Retrospective cohort study of 43,802 cancer patients | Cost calculations derived from multiple sources including Ontario Health Insurance Plan fees, Ministry of Health average costs. | Hospital care, nursing home, rehabilitation, ER, PC, medication costs, physician costs including GP and hospital. | 6 |
| Yu et al., Canada        | To assess the societal costs of EOL care associated with two places of death (hospital and home). | Prospective cohort design, 186 cancer caregivers | Caregivers interviewed every 2 weeks using AHCR. Outpatient, out-of-pocket and third-party costs were calculated as utilisation multiplied by a unit price. Caregiver time using a human capital approach. Hospitalisation costs estimated by the average cost of an episode weighted by a patient-specific adjustment factor. ER visits costed at a pre-defined cost per visit. | Hospitalisations, ER, outpatient costs (paid for by provincial government), out-of-pocket costs and caregiver time costs (paid by patient/carer), and third-party costs (e.g. insurers). | 9 |

PCT: primary care trust; ER: emergency room; AHCR: Ambulatory and Home Care Record; WELCAN: Welsh/Canadian; GP: general practitioner; PC: palliative care; EOL: end of life; DIN: Doctors Independent Network; MIMS: Monthly Index of Medical Specialties; OT: occupational therapist; RIV: Resource Intensity Weight; MCBS: Medicare Current Beneficiary Survey; IV: intravenous; HF: heart failure; RF-HI: Republic Fund of Health Insurance; NHS: National Health Service; HSPCs: home-specialised palliative care services.
Description of costing approaches used to derive costs

A wide variety of costing approaches were used to derive costs. These approaches varied significantly between different countries, largely dependent on the differing funding mechanisms for health care. For example, studies from the United States commonly utilised Medicare and Medicaid insurance claims’ data to calculate costs relating to palliative care. Medicare and Medicaid are national social insurance programmes which provide health coverage in the United States. Using Medicare or Medicaid data to calculate costs has the advantage that claims’ data represent the true cost to the insurer, and not a proxy or derived cost. However, it should be acknowledged that while claims’ data provides an accurate cost estimate, this only represents a narrow viewpoint for analysis as it fails to capture costs to third-party providers, patients/families or society. The apparent complexity of capturing truly comprehensive cost data is reflected in the fact that only one study from the United States attempted to describe costs that included both Medicare and non-Medicare expenditure.

In contrast, studies from the United Kingdom calculated costs using more diverse methodologies, due to the complex arrangement of commissioned publicly funded health services. For example, UK studies generally calculated hospital costs on the basis of national ‘tariffs’. A tariff is the cost attached to a grouping of healthcare units of similar resource need (a currency) and represents the cost paid by the commissioner not the actual cost to the healthcare provider. Approaches to deriving community and hospice costs were based on data which are generally considered to be even less accurate. UK community costs were commonly derived from nationally available ‘Unit Costs of Health and Social Care’. These unit cost estimates are calculated by the Personal Social Services Research Unit drawing together a range of routine data and research to provide estimates of national unit costs.

In the United Kingdom, the costs of hospice care are perhaps the most difficult to determine, with National Health Service (NHS) and voluntary sector providers funded in a variety of different ways. Georghiou and Bardsley attempted to calculate hospice costs based on national data but acknowledged ‘our estimate of the costs of hospice care at the end of life was based on crude
Table 4. Framework outlining perspectives of economic evaluations in palliative care and components of their related costs.

| Perspective                          | Types of cost                                      | Components of cost                                      | References |
|--------------------------------------|----------------------------------------------------|--------------------------------------------------------|------------|
| Hospital                             | Inpatient hospital admissions/bed days             | 8, 11–21, 23–26, 28–34, 40, 42–47                      |            |
|                                      | Personnel costs                                    | 13, 14, 40, 46                                         |            |
|                                      | Medical supplies, equipment and aids, etc.         | 8, 13, 14, 29                                          |            |
|                                      | Inpatient procedures (surgery, chemo, etc.)        | 13, 14, 17, 29                                         |            |
|                                      | Investigations, laboratory and diagnostic costs    | 8, 13–15, 17, 29, 43                                    |            |
|                                      | Drugs and medications                             | 8, 12–15, 40, 46                                       |            |
|                                      | Outpatient hospital admissions                     | 8, 12, 13–17, 21, 29, 30, 32–35, 38, 47               |            |
|                                      | ER visits                                          | 8, 12–14, 16, 21, 23, 30, 32, 43, 46, 47              |            |
|                                      | Ambulatory costs and transport                     | 8, 13, 14, 18–20, 43, 44                               |            |
|                                      | Hospital day care                                  | 12–14, 17                                              |            |
| Community/hospital-based             | Outpatient procedures (chemotherapy, etc.)        | 12–14, 43                                              |            |
|                                     | Chinese and herbal medicines                       | 15                                                     |            |
|                                     | Overhead costs (building costs and capital         | 40                                                     |            |
|                                     | personnel)                                         | 8, 13, 14, 17, 21, 23–26, 31, 34, 39–41               |            |
|                                     | Palliative care unit admission                     | 38, 46, 49                                             |            |
|                                     | Palliative care outpatient clinics                 | 24, 38, 49                                             |            |
|                                     | GP/family physician surgery visits                 | 8, 13, 14, 17, 21, 23–26, 31, 34, 39–41               |            |
|                                     | Medical and nursing home visits (GP, DN, etc.)     | 8, 13, 14, 17, 21, 24, 26, 29, 30, 38, 40             |            |
|                                     | Allied health home visits (physio, OT, mental health)| 8, 13, 14, 26, 29, 30, 38                             |            |
|                                     | Other home visits (social services, home care, other| 8, 11, 13, 14, 17, 26, 29, 30, 31, 33, 45             |            |
|                                     | caregivers)                                        | 12–14                                                  |            |
|                                     | Drugs and medications                             | 8, 13, 13, 14, 18–21, 24, 29, 31, 34, 40, 44          |            |
|                                     | Medical equipment, aids and adaptations            | 8, 11, 13, 14, 18–20, 45                               |            |
|                                     | Day care services                                  | 12–14                                                  |            |
|                                     | Stays in long-term care facilities, care homes,    | 8, 11, 18, 21, 28, 29, 32, 34, 44–46                   |            |
|                                     | nursing homes, skilled nursing facilities          | 13, 14, 18–20, 40                                      |            |
|                                     | Transportation                                     | 8, 13, 14, 31                                          |            |
|                                     | Diagnostic tests, laboratory costs                 | 13, 14, 26, 31                                         |            |
|                                     | Personal support (bathing, feeding, dressing, home| 11, 26                                                 |            |
|                                     | help)                                              | 31                                                     |            |
|                                     | Other social services (meals on wheels, etc.)      | 13, 14, 18–21, 24, 29, 31, 34, 40, 44                 |            |
|                                     | Nutritional counselling                           | 29                                                     |            |
|                                     | Dental services                                    | 40                                                     |            |
|                                     | Communication costs                               | 11, 46                                                 |            |
|                                     | Residential respite care and rehabilitation       | 40                                                     |            |
|                                     | Overhead costs                                    | 11                                                     |            |
|                                     | Direct payments made to users so they can 'buy'    | 11                                                     |            |
|                                     | their own services                                 | 8, 13, 14, 18–20, 43                                   |            |
| Hospice and specialist palliative    | Inpatient hospice stays/bed days                   | 8, 13–16, 21, 29, 30, 32, 34, 45                       |            |
| care                                 | Personnel costs                                    | 13, 14                                                 |            |
|                                     | Medical supplies                                  | 13, 14, 31                                             |            |
|                                     | Inpatient procedures                              | 13, 14                                                 |            |
|                                     | Investigations, laboratory and diagnostic costs    | 13, 14                                                 |            |
|                                     | Drugs and medications                             | 13, 14, 31                                             |            |
|                                     | Equipment and aids                                | 13, 14, 31                                             |            |
|                                     | Outpatient appointments and clinics               | 13, 14, 16                                             |            |
|                                     | Home hospice                                      | 12–14                                                  |            |
|                                     | Home visits from specialist palliative care       | 13, 14, 21, 24                                         |            |
|                                     | Start-up costs, e.g., for new community palliative| 40                                                     |            |
|                                     | care nursing service                              |                                                        |            |
| Informal care                       | Home caregivers                                   | 8, 13, 14                                              |            |
|                                     | Household help                                    | 13, 14                                                 |            |
|                                     | Equipment, aids, home adaptations                 | 8, 13, 15                                              |            |
|                                     | Medications                                       | 8, 13, 14                                              |            |
|                                     | Insurance payments                                | 8, 13, 14, 29                                         |            |
|                                     | Travel and accommodation expenses                 | 8, 13, 14                                              |            |
|                                     | Out-of-pocket expenses (parking, food/drink)       | 8, 13, 14, 18–20, 29, 47                              |            |
|                                     | Income lost from work                             | 8, 13–15, 18–20                                        |            |
|                                     | Caregiver time costs                              | 8, 13, 14, 18–20, 47                                   |            |
|                                     | Co-payments, e.g., shared with insurer/other       | 33                                                     |            |

ER: emergency room; GP: general practitioner; OT: occupational therapist.
aggregated measures of national hospice care use’ (p. 29). In addition to significant national differences in the way costs were calculated, differences were sometimes noted at a regional level. In Canada, for instance, unit costs for hospitalisation are agreed regionally by federal health authorities and differ, for example, between Ontario and Alberta meaning different costing approaches are required even within a single country.

Approaches to capturing costs incurred by patients and their families were particularly complex as these costs are split between direct outlays of money (out-of-pocket costs) and indirect or assumed costs related to lost income from work or caregiver time. The collection of data on direct costs usually relied on patient or caregiver self-report of actual costs, an approach that provides a ‘true’ cost but is susceptible to error and recall bias. In cases where participants were unable to recall an actual cost, Dumont et al. obtained an estimate by taking the average cost of the same item as provided by other participants. Approaches to capturing assumed or indirect costs were more complex. Chai et al., Yu et al. and Guerriere and Coyte used the human capital approach which assigns a monetary value to caregiver time using costs estimated from census data on average earnings. Dumont et al. used a similar approach whereby caregiver time costs were obtained based on an average monetary value attributed to household work in Canada for men and women.

**Description of data collection tools**

In general, the tools used to collect cost data were developed on an ad hoc basis for individual studies and were not standardised or validated tools. For example, Dumont et al. developed their study questionnaire through the Delphi procedure and generated questions in line with the validated Canadian Community Health Survey performed by Statistics Canada. Other authors extracted administrative or claims data directly into study-specific protocols. The study by Guerriere and Coyte proposed the use of a standardised framework for capturing costs in Canada: the Ambulatory and Home Care Record (AHCRAHR). This tool was designed to capture comprehensive costs and was subsequently validated and used in the studies by Chai et al. and Yu et al. The study by Mosoiu et al. also proposed a standardised costing framework for Romania; however, this was restricted to cost elements to the public healthcare system and did not include any costs from the viewpoint of third party or patient/family and society.

**Discussion**

This systematic review explored which costs are potentially relevant in economic evaluations of palliative care and identified approaches to collecting, and accurately costing, palliative care data. The findings suggest that a wide range of costs can be incurred during the palliative phase, costs that can be considered in four key domains: hospital care, community or home-based care, hospice care and informal care. Findings also suggest three key provider viewpoints to consider in economic analyses: state or government, insurers/third-party/not-for-profit organisations and patient and family and/or society. However, few studies in this review attempted to capture the full economic cost of palliative care with only eight papers collecting comprehensive cost data. Various reasons may account for this. Studies undertaken for specific organisations such as Regulatory Authorities may be required to conform to a specific perspective. This will vary on a national basis. For instance, in England, the National Institute for Health and Care Excellence (NICE) states that ‘productivity costs and costs borne by people using services and carers that are not reimbursed by the NHS or social services should not usually be included in any analyses. That is, a societal perspective will not normally be used’. It may also be reasonable to exclude certain costs if they are known to have little impact on the overall results. However, economic evaluations should be explicit about what has been included and excluded and provide justification for this.

The collection of data which captures the full economic cost of palliative care is an urgent priority. This has been highlighted in a recent report from the UK National End of Life Care Programme which noted that despite the existence of a range of costing information, ‘there are no robust, agreed costs of end of life care’. A necessary prerequisite to calculating the full economic cost of palliative care is an understanding of the potential range of costs to be included in any economic analysis. Our review provides an overview of the core cost components that are potentially relevant within each of four key domains and a framework for considering these costs from a variety of economic viewpoints. The framework identifies core cost components as identified by this review but is unlikely to be comprehensive and therefore should be considered a basic framework from which to build on. The range of cost components and the viewpoint from which analyses are undertaken are also necessarily context- and country specific. For example, in countries with comprehensive health coverage, the majority of hospital costs will be covered by state or third-party providers, while in low-income countries without comprehensive health coverage these costs will often be covered by patients and their families. Our framework is designed to be wide in scope and adaptable, with the intention that researchers from countries with differing funding mechanisms for palliative care can select the most appropriate cost components and viewpoints for their needs. All the studies in this review were from upper-middle or high-income countries, and there is a notable absence of data from lower income economies. Therefore, our proposed framework is likely to require further refinement to be suitable for
research in low-income countries. In countries where multiple providers (agencies) are involved in the delivery of palliative care, there is likely to be a range of cost, resource and other outcomes which are potentially relevant to any evaluation. In these situations, multi-agency cost consequence analysis in which all the impacts of an intervention across different sectors (e.g. hospital care, community care, social care) are reported in a disaggregated form may be helpful. This type of analysis highlights the distribution of effects across the system and allows potential economic barriers and perverse incentives to be managed.

Of particular note was the lack of studies in this review which explored costs from the viewpoint of patient and family, related to informal care. This is despite mounting evidence which highlights both the magnitude of these costs and the significant impact of the costs in terms of health and well-being. In a context of limited resources and growing demand for services, family carers are expected to shoulder an increasing burden of responsibility for palliative care provision. The associated financial costs to patient and family are significant, and it is imperative that these costs are accounted for as part of any full economic costing in palliative care. Our review findings support a recent UK report on the costs of dying at home which noted ‘economic analyses should reflect the cost to family members of caring, and should consider how savings to the state can be harnessed to support carers to continue to care at home’. The approaches used to capture cost data from patient and families are complex and may deter researchers from attempting to estimate these costs. Evidence suggests that these costs include both direct (out-of-pocket) and indirect costs (carer time costs, lost income, etc.). While estimates of direct costs to patient and family are relatively easy to capture using self-report measures such as those employed by Dumont et al. and Chai et al., the collection of indirect cost data is more complex. The human capital approach is often used for estimating time lost from employment; this approach applies the current average wages by age and sex categories to lost labour market time. Caregiver time lost from other household or leisure activities can be valued using replacement costs based on the average hourly wage of a homemaker. The use of methods such as these enables a consistent approach to the collection of patient and family data which are easily adapted by country and/or region. However, it should be acknowledged that these approaches are subject to limitations. The human capital approach is subject to market imperfections such as gender, race and other types of discrimination. In addition, both approaches generate crude population estimates of cost rather than the true cost to an individual. Finally, it should be noted that none of the studies in this review attempted to capture productivity costs, that is, productivity losses to employers. These costs should be acknowledged as an additional potential component of cost that could be considered under the societal perspective.

A wide range of approaches to capturing and deriving costs were identified in the included studies. Most approaches focused on hospital costs, which is not surprising given that inpatient hospital care is consistently identified as the most costly component of palliative care. Whatever approach is used, it is important that both unit quantities and costs/prices should be defined to ensure transparency. Approaches to capturing costs were generally specific to the country and healthcare funding system in which the study took place. The majority of the approaches are derived from North American literature; this presents a challenge to researchers from other countries as economic evidence does not transfer easily between countries or between different healthcare systems. For example, it is difficult to envisage how an approach solely utilising insurance claims’ data could be usefully adapted to a country with a largely state-funded healthcare system. Despite this, international comparisons on the economics of health provision clearly have value for gaining insight into the cost-effectiveness of various health systems and models of health care. Indeed, in recent years, the emergence of high quality and comparable international health and economic data in the field of ageing has allowed economic modelling through an international comparative lens. Therefore, while significant challenges still exist with the translation of health data between countries and health systems, there is clear potential for benefit if these challenges can be overcome.

Limitations

Searches were limited to English language articles so we cannot be completely confident that our searches were comprehensive. The majority of grey literature searches were from UK and North American sources; therefore, data from other countries may have been missed. Studies included in the review had variable rigour and relevance and generalisations should be considered with caution. The majority of studies in the review only included cancer patients, and findings may not be generalisable across other conditions.

Conclusion

Our review findings point to an urgent need for further research on the economic costs of palliative care. Research which captures the full economic cost should be prioritised in order to gain insight into the inter-relationships between different cost domains and different provider viewpoints and could build on the cost framework proposed here. Methodological developments are also required to generate novel approaches to data collection which provide more accurate cost estimates. These may include economic modelling approaches such as those which have recently been used to estimate costs of care in cancer. While some approaches will be country- or region specific, the value of
Internationally comparative economic data is significant and should drive further methodological developments in this area.

**Declaration of conflicting interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

**Ethical review**

No ethical review was required for this study.

**Funding**

The author(s) disclosed receipt of the following financial support for the research, authorship and/or publication of this article: This review was funded by a Vice Chancellor’s Fellowship at The University of Sheffield.

**References**

1. Gomes B, Cohen J, Deliens L, et al. International trends in circumstances of death and dying. In: Gott M and Ingleton C (eds) Living with ageing and dying: palliative and end of life care for older people. Oxford: Oxford University Press, 2011, pp. 3–18.
2. Murtagh F, Groeneveld I, Kaloki YE, et al. Capturing activity, costs, and outcomes: the challenges to be overcome for successful economic evaluation in palliative care. Prog Palliat Care 2013; 21(4): 232–235.
3. Drummond MF, O'Brien B, Stoddart GL, et al. Methods for the economic evaluation of health care programmes, 4th ed. Oxford: Oxford Medical Publications, 2015.
4. Higginson IJ, Evans CJ, Grande G, et al.; On behalf of MORECare. Evaluating complex interventions in End of Life Care: the MORECare Statement on good practice generated by a synthesis of expert perspectives and systematic reviews. BMC Med 2013; 11: 111.
5. Hughes-Hallett T, Craft A, Davies C, et al. Creating a fair and transparent funding system: the final report of the palliative care funding review. The Palliative Care Funding Review, London, July 2011.
6. Gardiner C, Brereton L, Frey R, et al. Exploring the financial impact of caring for family members receiving palliative and end-of-life care: a systematic review of the literature. Palliat Med 2014; 28(5): 375–390.
7. Evans C, Harding R and Higginson I; On behalf of MORECare. ‘Best practice’ in developing and evaluating palliative and end of life care services: a meta-synthesis of research methods for the MORECare project. Palliat Med 2013; 27(10): 885–898.
8. Guerriere DN and Coyte PT. The Ambulatory and Home Care Record: a methodological framework for economic analyses in end-of-life care. J Ageing Res 2011; 2011: 374237.
9. Pastrana T, Jünger S, Ostgathe C, et al. A matter of definition – key elements identified in a discourse analysis of definitions of palliative care. Palliat Med 2008; 22: 222–232.
10. Gough D, Oliver S and Thomas J (eds). An introduction to systematic reviews. London: SAGE, 2012.
11. Bardsley M, Georgihiou T and Dixon J. Social care and hospital use at the end of life. London: The Nuffield Trust, 2010.
12. Bentur N, Resnizky S, Balicer R, et al. Utilization and cost of services in the last 6 months of life of patients with cancer – with and without home hospice care. Am J Hosp Palliat Care 2014; 31(7): 723–725.
13. Chai H, Guerriere D, Zagorski B, et al. The magnitude, share and determinants of unpaid care costs for home-based palliative care service provision in Toronto, Canada. Health Soc Care Community 2014; 22(1): 30–39.
14. Chai H, Guerriere D, Zagorski B, et al. The size, share, and predictors of publicly financed healthcare costs in the home setting over the palliative care trajectory: a prospective study. J Palliat Care 2013; 29(3): 154–162.
15. Chan AT, Jacobs P, Yeo W, et al. The cost of palliative care for hepatocellular carcinoma in Hong Kong. Pharmacoeconomics 2001; 19(9): 947–953.
16. Chastek B, Harley C, Kallich J, et al. Health care costs for patients with cancer at the end of life. J Oncol Pract 2012; 8(6): 75s–80s.
17. Coyle D, Small N, Ashworth A, et al. Costs of palliative care in the community, in hospitals and in hospices in the UK. Crit Rev Oncol Hematol 1999; 32(2): 71–85.
18. Dumont S, Jacobs P, Fassbender K, et al. Costs associated with resource utilization during the palliative phase of care: a Canadian perspective. Palliat Med 2009; 23(8): 708–717.
19. Dumont S, Jacobs P, Fassbender K, et al. The trajectory of palliative care costs over the last 5 months of life: a Canadian longitudinal study. Palliat Med 2010; 24(6): 630–640.
20. Dumont S, Jacobs P, Fassbender K, et al. Distribution and sharing of palliative care costs in rural areas of Canada. J Palliat Care 2014; 30(2): 90–98.
21. Enguidanos SM, Cherin D, Brunley R, et al. Home-based palliative care study: site of death, and costs of medical care for patients with congestive heart failure, chronic obstructive pulmonary disease, and cancer. J Soc Work End Life Palliat Care 2005; 1(3): 37–56.
22. Georghiou T and Bardsley M. Exploring the cost of care at the end of life. London: The Nuffield Trust, 2014.
23. Gomez-Batiste X, Tuca A, Corrales E, et al. Resource consumption and costs of palliative care services in Spain: a multicenter prospective study. J Pain Symptom Manage 2010; 39(6): 75s–80s.
24. Coyle JF, Ruiz FJ, Greener MJ, et al. Palliative care treatment patterns and associated costs of healthcare resource use for specific advanced cancer patients in the UK. Eur J Cancer 2006; 42(1): 65–73.
25. Hanratty B, Burstrom B, Walander A, et al. Inequality in the face of death? Public expenditure on health care for different socioeconomic groups in the last year of life. J Health Serv Res Policy 2007; 12(2): 90–94.
26. Hanratty B, Jacoby A and Whitehead M. Socioeconomic differences in service use, payment and receipt of illness-related benefits in the last year of life: findings from the British Household Panel Survey. Palliat Med 2008; 22(3): 248–255.
27. Kohan C, Lunney J, Gabel J, et al. Medicare beneficiaries’ costs of care in the last year of life. Health Aff 2001; 20(4): 188–195.
28. Hollander MJ. Costs of end-of-life care: findings from the province of Saskatchewan. *Healthc Q* 2009; 12(3): 50–58.
29. Hoover DR, Crystal S, Kumar R, et al. Medical expenditures during the last year of life: findings from the 1992-1996 Medicare current beneficiary survey. *Health Serv Res* 2002; 37(6): 1625–1642.
30. Johnston K, Levy AR, Lorigan P, et al. Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: results from a retrospective, longitudinal survey (MELODY study). *Eur J Cancer* 2012; 48(14): 2175–2182.
31. Johnson A, Abernathy T, Howell D, et al. Resource utilisation and costs of palliative cancer care in an interdisciplinary health care model. *Palliat Med* 2009; 23(5): 448–459.
32. Kaul P, McAlister FA, Ezekowitz JA, et al. Resource use in the last 6 months of life among patients with heart failure in Canada. *Arch Intern Med* 2011; 171(3): 211–217.
33. Kim SJ, Han KT, Park EC, et al. Copayment policy effects on healthcare spending and utilization by Korean lung cancer patients at end of life: a retrospective cohort design 2003–2012. *Asian J Cancer Prev* 2014; 15(13): 5265–5270.
34. Koroukian SM, Beard H, Madigan E, et al. End-of-life expenditures by Ohio Medicaid beneficiaries dying of cancer. *Health Care Financ Rev* 2006; 28(2): 65–80.
35. Kovacevic A, Dragojevic-Simic V, Rancic N, et al. End-of-life costs of medical care for advanced stage cancer patients. *Vojnosanit Pregl* 2015; 72(4): 334–341.
36. Langton JM, Blanch B, Drew AK, et al. Retrospective studies of end-of-life resource utilization and costs in cancer care using health administrative data: a systematic review. *Palliat Med* 2014; 28(10): 1167–1196.
37. Ljungman D, Hytlander T and Lundholm K. Cost-utility estimations of palliative care in patients with pancreatic adenocarcinoma: a retrospective analysis. *World J Surg* 2013; 37(8): 1883–1891.
38. Marie Curie Cancer Care. *Understanding the cost of end of life care in different settings*, 2012, https://www.mariecurie.org.uk/globalassets/media/documents/commissioning-our-services/publications/understanding-cost-end-life-care-different-settingspdf
39. McBride T, Morton A, Nichols A, et al. Comparing the costs of alternative models of end-of-life care. *J Palliat Care* 2011; 27(2): 126–133.
40. Mosoiu D, Dumitrescu M and Connor SR. Developing a costing framework for palliative care services. *J Pain Symptom Manage* 2014; 48(4): 719–729.
41. Simoens S, Kutten B, Keirse E, et al. The costs of treating terminal patients. *J Pain Symptom Manage* 2010; 40(3): 436–448.
42. Smith S, Brick A and O’Hara S. Evidence on the cost and cost-effectiveness of palliative care: a literature review. *Palliat Med* 2014; 28(2): 130–150.
43. Tamir O, Singer Y and Shvartzman P. Taking care of terminally-ill patients at home – the economic perspective revisited. *Palliat Med* 2007; 21(6): 537–541.
44. Tangka FK, Subramanian S, Sabatino SA, et al. End-of-life medical costs of Medicaid cancer patients. *Health Serv Res* 2015; 50(3): 690–709.
45. Unroc KT, Greiner MA, Hernandez AF, et al. Resource use in the last 6 months of life among Medicare beneficiaries with heart failure, 2000–2007. *Arch Intern Med* 2011; 171(3): 196–203.
46. Walker H, Anderson M, Farahati F, et al. Resource use and costs of end-of-life/palliative care: Ontario adult cancer patients dying during 2002 and 2003. *J Palliat Care* 2011; 27(2): 79–88.
47. Yu M, Guerriere DN and Coyte PC. Societal costs of home and hospital end-of-life care for palliative care patients in Ontario, Canada. *Health Soc Care Community* 2015; 23(6): 605–618.
48. Gough D. Weight of evidence: a framework for the appraisal of the quality and relevance of evidence. *Res Pap Educ* 2007; 22(2): 213–228.
49. Banks J and Smith JP. *International comparisons in health economics: evidence from aging studies*. RAND Labour and Population working paper, October 2011, http://www.rand.org/pubs/working_papers/WR880.html (accessed 29 March 2016).
50. NHS England. Developing a new approach to palliative care funding. London: NHS England, 2015.
51. Curtis L. Unit costs of health and social care, 2015, http://www.pssru.ac.uk/project-pages/unit-costs/2015/index.php (accessed 30 March 2016).
52. National Institute for Health and Care Excellence (NICE). Guide to the methods of technology appraisal 2013, https://www.nice.org.uk/article/pmg9/chapter/foreword (accessed 18 April 2016).
53. National End of Life Care Programme. *Reviewing end of life care costing information to inform the QIPP end of life care workstream*, 2012, http://thewholeofsystem.co.uk/wp-content/uploads/2014/07/EoLC_QIPP_Costings_Report.pdf
54. The World Bank. *Country and lending group classifications* 2016, http://data.worldbank.org/about/country-and-lending-groups/#Upper_middle_income (accessed 29 March 2016).
55. Lysdahl KB, Mozygemba K, Burns J, et al. (eds). *Guidance for assessing effectiveness, economic aspects, ethical aspects, socio-cultural aspects and legal aspects in complex technologies*, http://www.integrate-ha.eu/downloads/ (accessed 18 April 2016).
56. Gardiner C, Bretenot L, Frey R, et al. Approaches to capturing the financial cost of family care-giving within a palliative care context: a systematic review. *Health Soc Care Community* 2016; 24: 519–531.
57. Gott M, Gardiner C, Allen R, et al. No matter what the cost: a qualitative study of the financial costs faced by family and whānau caregivers within a palliative care context. *Palliat Care* 2015; 29(6): 518–528.
58. Social Care Institute for Excellence (SCIE). *Dying well at home: the case for integrated working: SCIE guide 48*, 2013, http://www.scie.org.uk/publications/guides/guide48/59. Torgerson DJ, Donaldson C and Redi DM. Private vs social opportunity cost of time: valuing time in the demand for healthcare. *Healthc Q* 2011; 14(3): 194–195.